ClinicalTrials.gg
RecruitingNCT05838066Updated May 30, 2025

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

A Phase 3 interventional study of Recombinant Humanized Bispecific antibody against HER2,KN026 and HB1801 in First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, sponsored by Shanghai JMT-Bio Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Planned enrollment
21st of 248
880 · median 68
Started
2023
with 2 others
Phase 3
51 of 264
5 open now
Primary completion
2025-07
later than 6 of 25 live
Registered
248th of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 21st largest by planned enrollment of the 248 interventional ones that give a count, is one of 3 that started in 2023, is one of 51 in phase 3, reaches primary completion later than 6 of the 25 other live ones, and was the 248th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).

Read the detailed description

The purpose of this study is to assess the efficacy and safety of KN026 combined with HB1801 versus trastuzumab combined with pertuzumab and docetaxel as first-line treatment for HER2-positive recurrent or metastatic breast cancer. This study will establish an independent data monitoring committee (IDMC) to conduct safety assessments after approximately 20 subjects in the treatment group complete the first cycle of treatment. During the safety assessment period, the study will continue to enroll subjects, and safety review meetings will be at 1 year of randomization in the first subject. In addition, the IDMC plans to conduct one interim analysis of efficacy during the study period.

The primary study hypotheses are that the combination of KN026 combined with HB1801 is superior to trastuzumab combined with pertuzumab and docetaxel with respect to: Progression-free Survival (PFS) as assessed by the BIRC per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

03

Conditions studied

  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Voluntarily enrolled in this study and signed an form (ICF).
  • Age ≥ 18 years.
  • Recurrent or breast cancer confirmed by histology and/or cytology.
  • Latest tumor tissue sample confirmed as positive by central laboratory testing.
  • No prior systemic chemotherapy and/or HER2-targeted therapy for recurrent or metastatic breast cancer.
  • (ECOG) physical status score of 0 - 1.
  • Presence of lesion ( 1.1).
  • Adequate organ and bone marrow function

Key Exclusion Criteria:

  • Ineligible for any of the agents on the study
  • Untreated or unstable parenchymal metastases, spinal cord metastases or compression, or carcinomatous encephalitis.
  • Pregnant or lactating women.
  • Presence of other circumstances that may interfere with the subject's participation in the study procedures or are inconsistent with the maximum benefit of the subject's participation in the study or affect the results of the study: e.g., history of mental illness, drug or substance abuse, any other disease or condition of clinical significance, etc.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    KN026+HB1801

    Subjects will receive an intravenous (IV) infusion of KN026 plus HB1801. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurrs first.

    Drug: Recombinant Humanized Bispecific antibody against HER2,KN026 · Drug: HB1801

  • Active comparator
    Trastuzumab + Pertuzumab + Docetaxel

    On Day 1 of each 21-day cycle, patients will receive an intravenous (IV) infusion of Pertuzumab 840 mg loading dose followed by 420 mg per cycle, IV, D1, Q3W, in combination with trastuzumab 8 mg/kg loading dose followed by 6 mg/kg per cycle, IV, D1, Q3W and docetaxel 75 mg/m\^2. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurred first.

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Docetaxel

Interventions

  • DrugRecombinant Humanized Bispecific antibody against HER2,KN026

    IV infusion

  • DrugHB1801

    IV infusion

  • 840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion

  • 8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion

  • 75 mg/m\^2, D1 Q3W, IV infusion

06

What researchers measure

Primary outcomes

  1. Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. PFS (investigator assessment, RECIST1.1)

    Time frame: Up to approximately 4 years

  2. Overall survival (OS)

    Time frame: Up to approximately 4 years

  3. Objective response rate (ORR)

    Time frame: Up to approximately 4 years

  4. Disease control rate (DCR)

    Time frame: Up to approximately 4 years

  5. Duration of response (DoR)

    Time frame: Up to approximately 4 years

  6. Frequency and severity of TEAE and SAE

    Time frame: Up to approximately 4 years

  7. Concentration of KN026 in serum

    Time frame: Up to approximately 4 years

  8. Concentration of HB1801 in serum

    Time frame: Up to approximately 4 years

  9. Incidence of KN026 Anti-drug antibody (ADA) and neutralizing antibody (Nab) (if applicable)

    Time frame: Up to approximately 4 years

07

Study locations

1 of 1 sites recruiting
  • Clinical Trials Information Group
    Beijing, chaoyang, China
    Recruiting
    • Clinical Trials Information Group Officer · Contactctr-contact@mail.ecspc.com · +86-0311-69085587
    • Clinical Trials Information Group Officer · Contact+86-0311-69085587
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 1, 2023
StartActual
Jul 23, 2023
Primary completionEst.
Jul 31, 2025
CompletionEst.
Dec 31, 2027
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05838066
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Jul 23, 2023
Primary completion
Jul 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 30, 2025

Study contacts

Clinical Trials Information Group Officer
Contact
ctr-contact@mail.ecspc.com
+86-0311-69085587
fenglin She
Contact
shefenglin@cspc.cn
18301190515

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion